The association between serum TSH concentration and thyroid cancer

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1065-1072

  Boelaert, Kristien ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THYROTROPIN; THYROTROPIN RECEPTOR;

ASPIRATION BIOPSY; AUTOIMMUNE THYROIDITIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CANCER STAGING; DISEASE ASSOCIATION; HORMONE ACTION; HUMAN; INCIDENCE; NOTE; RISK ASSESSMENT; THYROID CANCER; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; TUMOR DIFFERENTIATION;

HUMANS; THYROID NEOPLASMS; THYROTROPIN;

EID: 72549096515     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0150     Document Type: Note

References (68)

1. 4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 17 1211-1223.
2. Baker JR Jr 1995 The immune response to papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 80 3419-3420.
3. Balme HW 1954 Metastatic carcinoma of the thyroid successfully treated with thyroxine. Lancet 266 812-813.
4. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, Regalbuto C & Vigneri R 1992 Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. American Journal of Medicine 93 363-369.
5. Biondi B, Filetti S & Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice. Endocrinology and Metabolism 1 32-40.
6. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC & Franklyn JA 2006 Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. Journal of Clinical Endocrinology and Metabolism 91 4295-4301. (Pubitemid 44833401)
7. Brabant G 2008 Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? Journal of Clinical Endocrinology and Metabolism 93 1167-1169.
8. Brewer C, Yeager N & Di CA 2007 Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Research 67 8002-8006.
9. British Thyroid Association and Royal College of Physicians 2007 Guidelines for the management of thyroid cancer. edn 2. www.british-thyroid- association.org.
10. Carayon P, Thomas-Morvan C, Castanas E & Tubiana M 1980 Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. Journal of Clinical Endocrinology and Metabolism 51 915-920. (Pubitemid 10024755)
11. Chang TC, Kuo SH, Liaw KY, Chang CC & Chen FW 1988 Cell kinetics, DNA content and TSH receptor-adenylate cyclase system in differentiated thyroid cancer. Clinical Endocrinology 29 477-484.
12. Cipolla C, Sandonato L, Graceffa G, Fricano S, Torcivia A, Vieni S, Latteri S & Latteri MA 2005 Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. American Surgeon 71 874-878.
13. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI & Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 1-33.
14. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167.
15. Dean DS & Hay ID 2000 Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7 229-239. (Pubitemid 30387658)
16. Derwahl M, Broecker M & Kraiem Z 1999 Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. Journal of Clinical Endocrinology and Metabolism 84 829-834.
17. Feldt-Rasmussen U 2001 Iodine and cancer. Thyroid 11 483-486.
18. Fenzi GF, Ceccarelli C, Macchia E, Monzani F, Bartalena L, Giani C, Ceccarelli P, Lippi F, Baschieri L & Pinchera A 1985 Reciprocal changes of serum thyroglobulin and TSH in residents of a moderate endemic goitre area. Clinical Endocrinology 23 115-122. (Pubitemid 15015332)
19. Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R & Ingbar SH 1988 The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer. New England Journal of Medicine 318 753-759. (Pubitemid 18090258)
20. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, Pinchera A & Vitti P 2009 Lower levels of TSH are associated to a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocrine-Related Cancer 16 1251-1260.
21. Franceschi S 1998 Iodine intake and thyroid carcinoma - a potential risk factor. Experimental and Clinical Endocrinology and Diabetes 106 S38-S44. (Pubitemid 28534914)
22. Gharib H 2004 Changing trends in thyroid practice: understanding nodular thyroid disease. Endocrine Practice 10 31-39.
23. Goldberg RC, Lindsay S, Nichols CW Jr & Chaikoff IL 1964 Induction of neoplasms in thyroid glands of rats by subtotal thyroidectomy and by the injection of one microcurie of I-131. Cancer Research 24 35-43.
24. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT, He H, Blondal T, Geller F, Jakobsdottir M et al. 2009 Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nature Genetics 41 460-464.
25. Hales IB, McElduff A, Crummer P, Clifton-Bligh P, Delbridge L, Hoschl R, Poole A, Reeve TS, Wilmshurst E & Wiseman J 1992 Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 75 886-889.
26. Haymart MR 2009 Understanding the relationship between age and thyroid cancer. Oncologist 14 216-221.
27. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC & Chen H 2008a Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. Journal of Clinical Endocrinology and Metabolism 93 809-814.
28. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC & Chen H 2008b Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clinical Endocrinology [in press].
29. Hegedus L 2004 Clinical practice. The thyroid nodule. New England Journal of Medicine 351 1764-1771.
30. Hegedus L, Bonnema SJ & Bennedbaek FN 2003 Management of simple nodular goiter: current status and future perspectives. Endocrine Reviews 24 102-132. (Pubitemid 36223282)
31. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA & Braverman LE 2002 Serum TSH T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). Journal of Clinical Endocrinology and Metabolism 87 489-499.
32. Holm LE, Blomgren H & Lowhagen T 1985 Cancer risks in patients with chronic lymphocytic thyroiditis. New England Journal of Medicine 312 601-604. (Pubitemid 15133674)
33. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA & Smit JW 2007 Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 92 2610-2615. (Pubitemid 47037365)
34. Ichikawa Y, Saito E, Abe Y, Homma M & Muraki T 1976 Presence of TSH receptor in thyroid neoplasms. Journal of Clinical Endocrinology and Metabolism 42 395-398.
35. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J et al. 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16 1229-1242. (Pubitemid 46080167)
36. Jonklaas J, Nsouli-Maktabi H & Soldin SJ 2008 Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid 18 943-952.
37. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE & Roger PP 2001 Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocrine Reviews 22 631-656. (Pubitemid 32955247)
38. Kurukahvecioglu O, Taneri F, Yuksel O, Aydin A, Tezel E & Onuk E 2007 Total thyroidectomy for the treatment of Hashimoto's thyroiditis coexisting with papillary thyroid carcinoma. Advances in Therapy 24 510-516. (Pubitemid 47295427)
39. Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P & Gomez I 1998 Epidemiology of thyroid diseases in iodine sufficiency. Thyroid 8 1179-1183. (Pubitemid 29042553)
40. Mann K 1998 Evaluation of risk in autonomously functioning thyroid nodules. Experimental and Clinical Endocrinology & Diabetes 106 S23-S26.
41. Marqusee E, Benson CB, Frates MC, Doubilet PM, Larsen PR, Cibas ES & Mandel SJ 2000 Usefulness of ultrasonography in the management of nodular thyroid disease. Annals of Internal Medicine 133 696-700. (Pubitemid 30822660)
42. Matsuo K, Friedman E, Gejman PV & Fagin JA 1993 The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. Journal of Clinical Endocrinology and Metabolism 76 1446-1451. (Pubitemid 23164359)
43. Mazzaferri EL 1999 An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9 421-427. (Pubitemid 29244917)
44. Mazzaferri EL 2000 Thyroid cancer and Graves' disease: the controversy ten years later. Endocrine Practice 6 221-225.
45. Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97 418-428. (Pubitemid 24345593)
46. Nagataki S & Nystrom E 2002 Epidemiology and primary prevention of thyroid cancer. Thyroid 12 889-896. (Pubitemid 35332993)
47. Okayasu I, Fujiwara M, Hara Y, Tanaka Y & Rose NR 1995 Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer 76 2312-2318.
48. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbrini R & Pacella CM 1998 Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. Journal of Clinical Endocrinology and Metabolism 83 780-783. (Pubitemid 28496445)
49. Pellegriti G, Belfiore A, Giuffrida D, Lupo L & Vigneri R 1998 Outcome of differentiated thyroid cancer in Graves' patients. Journal of Clinical Endocrinology and Metabolism 83 2805-2809. (Pubitemid 28493780)
50. Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D, Flaris N, Leontsini M, Kourtis A & Avramidis A 2008 Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. Journal of Cancer Research and Clinical Oncology 134 953-960.
51. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J & Jaffiol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 81 4318-4323. (Pubitemid 26412036)
52. Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R & Schumm-Draeger PM 2004 Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid 14 926-932. (Pubitemid 39612911)
53. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA & Boice JD Jr 1995 Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiation Research 141 259-277.
54. Ross DS 2006 Predicting thyroid malignancy. Journal of Clinical Endocrinology and Metabolism 91 4253-4255.
55. Sanders LE & Cady B 1998 Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Archives of Surgery 133 419-425. (Pubitemid 28193527)
56. Satta MA, De RG, Testa A, Maussier ML, Valenza V, Rabitti C, Saletnich I, D'Ugo D & Picciocchi A 1993 Thyroid cancer in suppressed contralateral lobe of patients with hot thyroid nodule. European Journal of Cancer 29A 1190-1192.
57. Shi Y, Zou M & Farid NR 1993 Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis. Clinical Endocrinology 39 269-274. (Pubitemid 23274424)
58. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK & Sutcliffe SB 1988 Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. International Journal of Radiation Oncology, Biology, Physics 14 1063-1075. (Pubitemid 18178792)
59. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A & Shah JP 1999 Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 126 1070-1076.
60. Surks MI & Hollowell JG 2007 Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. Journal of Clinical Endocrinology and Metabolism 92 4575-4582.
61. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T & Smith PA 1977 The spectrum of thyroid disease in a community: the Whickham survey. Clinical Endocrinology 7 481-493. (Pubitemid 8235965)
62. Vander JB, Gaston EA & Dawber TR 1968 The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Annals of Internal Medicine 69 537-540.
63. Vermiglio F, Lo P, Violi MA, Moleti M, Castagna MG, Finocchiaro MD, Mattina F, Mandolfino M, Zimbaro G & Trimarchi F 2003 Changes in both size and cytological features of thyroid nodule after levothyroxine treatment. Clinical Endocrinology 59 347-353. (Pubitemid 37046988)
64. Du Villard JA, Wicker R, Crespo P, Russo D, Filetti S, Gutkind JS, Sarasin A & Suarez HG 2000 Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation. Oncogene 19 4896-4905. (Pubitemid 30809026)
65. Walker RP & Paloyan E 1990 The relationship between Hashimoto's thyroiditis, thyroid neoplasia, and primary hyperparathyroidism. Otolaryngologic Clinics of North America 23 291-302. (Pubitemid 20139194)
66. Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K & Ito K 2007 Recent outcome of Graves' disease patients with papillary thyroid cancer. European Journal of Endocrinology 157 325-329. (Pubitemid 47603537)
67. Yeager N, Klein-Szanto A, Kimura S & Di CA 2007 Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Research 67 959-966.
68. Zelmanovitz F, Genro S & Gross JL 1998 Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. Journal of Clinical Endocrinology and Metabolism 83 3881-3885. (Pubitemid 28513566)